Effect of Recombinant Erythropoietin on Numbers of Circulating Endothelial Progenitor Cells in People With Persistent Symptoms During the Subacute Period After Traumatic Brain Injury

NCT02226848 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

NIH

Sponsor class

Conditions

Traumatic Brain Injury

Interventions

DRUG: Erythropoeitin

Sponsor

National Institute of Neurological Disorders and Stroke (NINDS)